Ratings Sinocare Inc.

Equities

300298

CNE100001CJ0

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
23.5 ^CNY	-0.68%		+0.17%	-22.70%

Apr. 26	Sinocare Inc. Proposes Final Dividend for 2023	CI
Apr. 25	Sinocare Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 46% by 2026.
The company's profit outlook over the next few years is a strong asset.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

With a 2024 P/E ratio at 30.52 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is highly valued given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
SINOCARE INC.	-22.70%	1.8B	-
ABBOTT LABORATORIES	-5.43%	181B	C+
MEDTRONIC PLC	+4.30%	114B	C
BECTON, DICKINSON AND COMPANY	-3.09%	68.29B	A
DEXCOM, INC.	+5.86%	52.24B	B-
CENCORA, INC.	+8.15%	44.3B	B-
HOYA CORPORATION	+7.52%	42.73B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+25.54%	32.52B	B
TERUMO CORPORATION	+17.85%	26.02B	A-
WEST PHARMACEUTICAL SERVICES, INC.	+1.00%	25.91B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes